8 Antibiotic Classes and the Infections Each One Targets

5. Tetracycline Antibiotics - Versatile Broad-Spectrum Agents

Tetracyclines, encompassing tetracycline, doxycycline, and minocycline, achieve their antimicrobial effects through reversible binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome and thereby inhibiting bacterial protein synthesis in a bacteriostatic manner. These broad-spectrum antibiotics demonstrate exceptional activity against a diverse range of pathogens, including gram-positive and gram-negative bacteria, atypical organisms, rickettsiae, and certain protozoa, making them particularly valuable for treating tick-borne diseases such as Rocky Mountain spotted fever, Lyme disease, and ehrlichiosis. The lipophilic properties of newer tetracyclines like doxycycline and minocycline enable excellent tissue penetration, including the ability to cross the blood-brain barrier, making them effective for treating central nervous system infections and conditions requiring prolonged tissue exposure such as acne vulgaris and rosacea. Tetracyclines serve as important first-line agents for sexually transmitted infections, particularly those caused by Chlamydia trachomatis and Ureaplasma urealyticum, while also providing effective treatment for respiratory tract infections caused by Mycoplasma pneumoniae and Chlamydophila pneumoniae. The unique spectrum of tetracyclines extends to uncommon but serious infections such as plague, tularemia, and anthrax, positioning them as critical agents in bioterrorism preparedness, though their use is limited in children under eight years of age and pregnant women due to potential effects on developing teeth and bones.

6. Glycopeptide Antibiotics - The Gram-Positive Specialists

Glycopeptide antibiotics, primarily represented by vancomycin and teicoplanin, function as bactericidal agents by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cell wall synthesis and ultimately leading to bacterial cell lysis. These antibiotics demonstrate exquisite specificity for gram-positive bacteria, making them invaluable for treating serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci, and ampicillin-resistant enterococci, particularly in healthcare-associated settings where these resistant organisms are prevalent. Vancomycin serves as the gold standard for treating MRSA bacteremia, endocarditis, pneumonia, and complicated skin and soft tissue infections, with its efficacy dependent on achieving appropriate serum trough concentrations to ensure adequate tissue penetration while minimizing the risk of nephrotoxicity. The unique mechanism of action of glycopeptides makes them essential for treating Clostridioides difficile-associated colitis when administered orally, as vancomycin achieves high concentrations in the gastrointestinal tract without significant systemic absorption, effectively eliminating the pathogen while minimizing systemic side effects. However, the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-intermediate Staphylococcus aureus (VISA) has highlighted the importance of judicious use and appropriate dosing strategies, while newer agents like linezolid and daptomycin provide alternative options for treating glycopeptide-resistant gram-positive infections, though vancomycin remains a cornerstone of therapy for serious MRSA infections.